Clinical efficacy of adjuvant chemotherapy in stage IB (< 4 cm) non-small cell lung cancer patients with high-risk factors
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Adjuvant chemotherapy is the standard of care for resected stage II-IIIA non-small cell lung cancer (NCSLC). The efficacy of adjuvant chemotherapy in stage IB (< 4 cm) NSCLC with high-risk factors is controversial. Methods: This retrospective multicenter study included 285 stage IB NSCLC patients with high-risk factors according to the 8th edition tumor, node, metastasis (TNM) classification from four academic hospitals. High-risk factors included visceral pleural invasion, vascular invasion, lymphatic invasion, lung neuroendocrine tumors, and micropapillary histology patterns. Results: Of the 285 patients, 127 (44.6%) were included in the adjuvant chemotherapy group and 158 (55.4%) were included in the non-adjuvant chemotherapy group. The median follow-up was 41.5 months. Patients in the adjuvant chemotherapy group had a significantly reduced recurrence rate and risk of mortality than those in the non-adjuvant chemotherapy group (hazards ratio, 0.408; 95% confidence interval, 0.221 to 0.754; p = 0.004 and hazards ratio, 0.176; 95% confidence interval, 0.057 to 0.546; p = 0.003, respectively). Adjuvant chemotherapy should be particularly considered for the highrisk factors such as visceral pleural involvement or vascular invasion. Based on the subgroup analysis, adjuvant chemotherapy should be considered when visceral pleural involvement is present, even if the tumor size is < 3 cm. Conclusions: Adjuvant chemotherapy may be useful for patients with stage IB NSCLC with high-risk factors and is more relevant for patients with visceral pleural involvement or vascular invasion.
Abstract
Background/Aims: Adjuvant chemotherapy is the standard of care for resected stage II-IIIA non-small cell lung cancer (NCSLC). The efficacy of adjuvant chemotherapy in stage IB (< 4 cm) NSCLC with high-risk factors is controversial. Methods: This retrospective multicenter study included 285 stage IB NSCLC patients with high-risk factors according to the 8th edition tumor, node, metastasis (TNM) classification from four academic hospitals. High-risk factors included visceral pleural invasion, vascular invasion, lymphatic invasion, lung neuroendocrine tumors, and micropapillary histology patterns. Results: Of the 285 patients, 127 (44.6%) were included in the adjuvant chemotherapy group and 158 (55.4%) were included in the non-adjuvant chemotherapy group. The median follow-up was 41.5 months. Patients in the adjuvant chemotherapy group had a significantly reduced recurrence rate and risk of mortality than those in the non-adjuvant chemotherapy group (hazards ratio, 0.408; 95% confidence interval, 0.221 to 0.754; p = 0.004 and hazards ratio, 0.176; 95% confidence interval, 0.057 to 0.546; p = 0.003, respectively). Adjuvant chemotherapy should be particularly considered for the highrisk factors such as visceral pleural involvement or vascular invasion. Based on the subgroup analysis, adjuvant chemotherapy should be considered when visceral pleural involvement is present, even if the tumor size is < 3 cm. Conclusions: Adjuvant chemotherapy may be useful for patients with stage IB NSCLC with high-risk factors and is more relevant for patients with visceral pleural involvement or vascular invasion.
참고문헌 (21)
- Naylor EC, "Targeted therapy and immunotherapy for lung cancer", Surg Oncol Clin N Am, 25, pp.601~609 (2016)
- Lou F, "Differences in patterns of recurrence in early-stage versus locally advanced non-small cell lung cancer", Ann Thorac Surg, 98, pp.1755~1760 (2014)
- ) : a randomised controlled trial, "Lancet Oncol", 2006, 719~727
- Strauss GM, "Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer : CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups", J Clin Oncol, 26, pp.5043~5051 (2008)
- He J, "Adjuvant chemotherapy for the completely resected stage IB nonsmall cell lung cancer: a systematic review and meta-analysis", Medicine(Baltimore), 94, pp.e903~ (2015)
- Schmid-Bindert G, "A randomized phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II non-small-cell lung cancer", Lung Cancer, 90, pp.397~404 (2015)
- Peng S, "Effect of adjuvant chemotherapy on DFS for patients with stage I NSCLC", Zhongguo Fei Ai Za Zhi, 20, pp.485~489 (2017)
- Yanagawa N, "The clinical impact of solid and micropapillary patterns in resected lung adenocarcinoma", J Thorac Oncol, 11, pp.1976~1983 (2016)
- Ma M, "Micropapillary or solid pattern predicts recurrence free survival benefit from adjuvant chemotherapy in patients with stage IB lung adenocarcinoma", J Thorac Dis, 10, pp.5384~5393 (2018)
- Yuan Y, "Presence of micropapillary and solid patterns are associated with nodal upstaging and unfavorable prognosis among patient with cT1N0M0 lung adenocarcinoma : a large-scale analysis", J Cancer Res Clin Oncol, 144, pp.743~749 (2018)
- Nentwich MF, "Lymphatic invasion predicts survival in patients with early node-negative non-small cell lung cancer", J Thorac Cardiovasc Surg, 146, pp.781~787 (2013)
- Higgins KA, "Lymphovascular invasion in non-small-cell lung cancer : implications for staging and adjuvant therapy", J Thorac Oncol, 7, pp.1141~1147 (2012)
- Koike T, "Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non-small cell lung cancer", J Thorac Cardiovasc Surg, 146, pp.372~378 (2013)
- Qian F, "Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma", J Thorac Cardiovasc Surg, 155, pp.1227~1235 (2018)[DOI]
- Okada M, "Effect of tumor size on prognosis in patients with non-small cell lung cancer : the role of segmentectomy as a type of lesser resection", J Thorac Cardiovasc Surg, 129, pp.87~93 (2005)
- Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S), "Clinical tumour size and prognosis in lung cancer", Eur Respir J, 14, pp.812~816 (1999)
- Yoshida J, "Visceral pleura invasion impact on non-small cell lung cancer patient survival : its implications for the forthcoming TNM staging based on a largescale nation-wide database", J Thorac Oncol, 4, pp.959~963 (2009)
- Kato H, "A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung", N Engl J Med, 350, pp.1713~1721 (2004)
- Winton T, "Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer", N Engl J Med, 352, pp.2589~2597 (2005)
- Bennouna J, "Impact of histology on survival of resected non-small cell lung cancer(NSCLC)receiving adjuvant chemotherapy : subgroup analysis of the adjuvant vinorelbine(NVB)cisplatin(CDDP)versus observation in the ANITA trial", Lung Cancer, 74, pp.30~34 (2011)
- Park SY, "Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer", J Cardiothorac Surg, 8, pp.151~ (2013)